Home
Per Eystein Lønning's picture

Per Eystein Lønning

Professor
  • E-mailPer.Lonning@uib.no
  • Phone+47 55 97 20 10+47 55 97 20 27
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning is the head of the breast cancer research group at Mohn cancer research laboratory. he has a continuous work record in cancer therapy and science since 1982. He was employed as a consultant in oncology at Haukeland University Hospital in 1990, and became professor at the University of Bergen in 1992. The breast cancer group currently includes about 20 members. The work is centered on translational research in breast cancer; the group however also runs projects related to colorectal cancers and melanomas. The team include senior researchers 7 postdocs / PhD candidates as well as technical staff members in the laboratory but also physicians seeing patients at the Department of Oncology, several of whom in addition work part-time on their projects in the laboratory. Professor Lønnings main area of interest has been mechanism related to therapy failure in the area of endocrine as well as chemotherapy for breast cancer. In addition, he has had an interest in genetic and epigenetic cancer risk factors. His current main field of research relates to chemotherapy resistance.

Academic article
  • Show author(s) 2013. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLOS ONE. 12 pages.
  • Show author(s) 2013. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 2790-2797.
  • Show author(s) 2013. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLOS ONE.
  • Show author(s) 2012. Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic advances in medical oncology.
  • Show author(s) 2012. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine. 1033-1042.
  • Show author(s) 2012. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer. 6 pages.
  • Show author(s) 2011. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription.
  • Show author(s) 2010. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. European Journal of Cancer. 2127-2133.
  • Show author(s) 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • Show author(s) 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • Show author(s) 2010. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • Show author(s) 2010. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
  • Show author(s) 2010. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
  • Show author(s) 2010. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 13 pages.
  • Show author(s) 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
  • Show author(s) 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • Show author(s) 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • Show author(s) 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • Show author(s) 2009. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • Show author(s) 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • Show author(s) 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • Show author(s) 2009. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
  • Show author(s) 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Show author(s) 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
  • Show author(s) 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • Show author(s) 2008. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 5562-5571.
  • Show author(s) 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • Show author(s) 2008. Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 987-997.
  • Show author(s) 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • Show author(s) 2008. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
  • Show author(s) 2008. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
  • Show author(s) 2008. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 90-95.
  • Show author(s) 2007. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
  • Show author(s) 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • Show author(s) 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • Show author(s) 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
  • Show author(s) 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
  • Show author(s) 2007. Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
  • Show author(s) 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • Show author(s) 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
  • Show author(s) 2007. Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
  • Show author(s) 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • Show author(s) 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • Show author(s) 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • Show author(s) 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
  • Show author(s) 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • Show author(s) 2006. Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 47.
  • Show author(s) 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • Show author(s) 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Show author(s) 2006. Antitumor efficacy improved by local delivery of species-specific endostatin. Journal of Neurosurgery. 118-128.
  • Show author(s) 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
  • Show author(s) 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • Show author(s) 2005. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncology Reports. 525-530.
  • Show author(s) 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • Show author(s) 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • Show author(s) 2005. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implication. Clinical Cancer Research. 878s-883s.
  • Show author(s) 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
  • Show author(s) 2005. Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 723-728.
  • Show author(s) 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • Show author(s) 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • Show author(s) 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • Show author(s) 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Show author(s) 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Show author(s) 2003. Study of suboptimum treatment response: lessons from breast cancer. The Lancet. 177-185.
  • Show author(s) 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • Show author(s) 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Show author(s) 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Show author(s) 2003. Pharmacokinetics of third-generation aromatase inhibitors. Seminars in Oncology. 23-32.
  • Show author(s) 2003. Development of aromatase inhibitors and their pharmacologic profile. American Journal of Clinical Oncology. S3-S8.
  • Show author(s) 2003. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clinical Pharmacokinetics. 619-631.
  • Show author(s) 2002. The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology. 265-270.
  • Show author(s) 2002. The TP53 Codon 72 Polymorphism May Affect the Function of TP53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas. Cancer Epidemiology, Biomarkers and Prevention. 1684-1688.
  • Show author(s) 2002. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. Journal of Steroid Biochemistry and Molecular Biology. 95-102.
  • Show author(s) 2002. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 161-175.
  • Show author(s) 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 12963-12968.
  • Show author(s) 2002. Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients. American Journal of Oncology Review. 99-102.
  • Show author(s) 2002. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology. 751-757.
  • Show author(s) 2002. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs & Aging. 277-298.
  • Show author(s) 2002. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Human Gene Therapy. 1115-1125.
  • Show author(s) 2001. Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 39-47.
  • Show author(s) 2001. Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • Show author(s) 2000. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Show author(s) 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • Show author(s) 2000. Pharmacology and clinical experience with exemestane. Expert Opinion on Investigational Drugs. 1897-1905.
  • Show author(s) 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • Show author(s) 2000. Molecular portraits of human breast tumours. Nature. 747-752.
  • Show author(s) 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • Show author(s) 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • Show author(s) 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • Show author(s) 2000. Endocrine therapy for treatment of breast cancer. Polish Oncology. 50-53.
  • Show author(s) 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • Show author(s) 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • Show author(s) 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • Show author(s) 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Show author(s) 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Show author(s) 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • Show author(s) 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • Show author(s) 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • Show author(s) 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Show author(s) 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • Show author(s) 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • Show author(s) 1998. Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • Show author(s) 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • Show author(s) 1997. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • Show author(s) 1997. Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • Show author(s) 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • Show author(s) 1997. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Show author(s) 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Show author(s) 1997. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Show author(s) 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Show author(s) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Show author(s) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Show author(s) 1997. Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • Show author(s) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Show author(s) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Show author(s) 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Show author(s) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Show author(s) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Show author(s) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Show author(s) 1996. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer, Predictive Oncology. 335-339.
  • Show author(s) 1996. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • Show author(s) 1996. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • Show author(s) 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Show author(s) 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Show author(s) 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Show author(s) 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Show author(s) 1995. Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
  • Show author(s) 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Show author(s) 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Show author(s) 1994. Primærbehandling av lokalavansert brystkreft med bruk av neoadjuvant kjemoterapi. Tidsskrift for Den norske legeforening. 668-670.
  • Show author(s) 1994. Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • Show author(s) 1993. Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews. 65-77.
  • Show author(s) 1993. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
  • Show author(s) 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Show author(s) 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Show author(s) 1993. Dose response evaluation - Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics. 1-5.
  • Show author(s) 1993. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
  • Show author(s) 1992. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aramotisation in breast cancer patients. European Journal of Cancer. 1712-1716.
  • Show author(s) 1992. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer. 692-697.
  • Show author(s) 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Show author(s) 1992. Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Show author(s) 1992. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Show author(s) 1992. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patient on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment. 57-62.
  • Show author(s) 1992. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Show author(s) 1992. Aromatase inhibitors in malignant diseases of aging. Drugs & Aging. 530-545.
  • Show author(s) 1992. Aromatase activity, plasma oestradiol and their correlation with demographic indices in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 769-771.
  • Show author(s) 1991. Wie wirkungsvoll ist das Mammographie-Screening? Deutsche Medizinische Wochenschrift. 108-112.
  • Show author(s) 1991. Treatment of early breast cancer with conservation of the breast. Acta Oncologica. 779-792.
  • Show author(s) 1991. Treatment of breast cancer with aromatase inhibitors. Medicamentos de actualidad. 117-132.
  • Show author(s) 1991. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer. 789-793.
  • Show author(s) 1991. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology. 367-372.
  • Show author(s) 1991. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of enzyme inhibition (Print). 315-325.
  • Show author(s) 1991. Leser-Zuschriften - Mammographie-Screening. Deutsche Medizinische Wochenschrift. 636-637.
  • Show author(s) 1991. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients. British Journal of Cancer. 887-894.
  • Show author(s) 1991. Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Show author(s) 1991. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Show author(s) 1991. Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
  • Show author(s) 1991. Aromatase inhibitors - future prospects. Int Congr Symp Series. 55-59.
  • Show author(s) 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
  • Show author(s) 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
  • Show author(s) 1990. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megastrol acetate in postmenopausal patients with advanced brea cancer. Cancer Chemotherapy and Pharmacology. 101-105.
  • Show author(s) 1990. Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Academic lecture
  • Show author(s) 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • Show author(s) 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • Show author(s) 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • Show author(s) 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • Show author(s) 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • Show author(s) 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • Show author(s) 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • Show author(s) 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • Show author(s) 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Academic anthology/Conference proceedings
  • Show author(s) 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Abstract
  • Show author(s) 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • Show author(s) 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • Show author(s) 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • Show author(s) 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • Show author(s) 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • Show author(s) 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Show author(s) 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • Show author(s) 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • Show author(s) 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Show author(s) 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Academic literature review
  • Show author(s) 2019. Constitutional mosaic epimutations - A hidden cause of cancer? Cell stress. 118-135.
  • Show author(s) 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. Journal of Clinical Oncology. 1580-1583.
  • Show author(s) 2015. Estradiol measurement in translational studies of breast cancer. Steroids. 26-31.
  • Show author(s) 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy. 681-700.
  • Show author(s) 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene. 5315-5330.
  • Show author(s) 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer. R183-R201.
  • Show author(s) 2012. P53 and its molecular basis to chemoresistance in breast cancer. Expert opinion on therapeutic targets. S23-S30.
  • Show author(s) 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology. 503-514.
  • Show author(s) 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. Clinical Cancer Research. 4948-4958.
  • Show author(s) 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy. 1825-1836.
  • Show author(s) 2010. Molecular basis for therapy resistance. Molecular Oncology. 284-300.
  • Show author(s) 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? European Journal of Cancer. 527-535.
  • Show author(s) 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Show author(s) 2009. Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncologica. 1092-1101.
  • Show author(s) 2008. Indications and limitations of third-gene ration aromatase inhibitors. Expert Opinion on Investigational Drugs. 723-739.
  • Show author(s) 2007. Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. 1293-1306.
  • Show author(s) 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology. 53-61.
  • Show author(s) 2004. Aromatase inhibitors in breast cancer. Endocrine-Related Cancer. 179-189.

More information in national current research information system (CRIStin)

Fields of competence